BRIEF-Arvinas And Pfizer Enter Into A Transaction With Rigel Pharmaceuticals For The Exclusive Global Rights Of Veppanu

Arvinas

ARVN

0.00

Pfizer

PFE

0.00

May 12 (Reuters) - Arvinas Inc ARVN.O:

ARVINAS AND PFIZER ENTER INTO A TRANSACTION WITH RIGEL PHARMACEUTICALS FOR THE EXCLUSIVE GLOBAL RIGHTS OF VEPPANU (VEPDEGESTRANT)
ARVINAS AND PFIZER ENTER INTO A TRANSACTION WITH RIGEL PHARMACEUTICALS FOR THE EXCLUSIVE GLOBAL RIGHTS OF VEPPANU (VEPDEGESTRANT)
ARVINAS INC - AND PFIZER TO RECEIVE $85 MILLION IN UPFRONT AND TRANSITION PAYMENTS
ARVINAS INC - AND PFIZER ELIGIBLE FOR UP TO $320 MILLION IN MILESTONE PAYMENTS AND TIERED ROYALTIES
ARVINAS INC - RIGEL TO CONTRIBUTE UP TO $40 MILLION TOWARDS ONGOING DEVELOPMENT ACTIVITIES

Source text: ID:nGNXQfxCj

Further company coverage: ARVN.O

More This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.